Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Issue 6 (28th January 2016)
- Record Type:
- Journal Article
- Title:
- Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Issue 6 (28th January 2016)
- Main Title:
- Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups
- Authors:
- Thomas, Christian
Sill, Martin
Ruland, Vincent
Witten, Anika
Hartung, Stefan
Kordes, Uwe
Jeibmann, Astrid
Beschorner, Rudi
Keyvani, Kathy
Bergmann, Markus
Mittelbronn, Michel
Pietsch, Torsten
Felsberg, Jörg
Monoranu, Camelia M.
Varlet, Pascale
Hauser, Peter
Olar, Adriana
Grundy, Richard G.
Wolff, Johannes E.
Korshunov, Andrey
Jones, David T.
Bewerunge-Hudler, Melanie
Hovestadt, Volker
von Deimling, Andreas
Pfister, Stefan M.
Paulus, Werner
Capper, David
Hasselblatt, Martin - Abstract:
- Abstract: Background: Choroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowledge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence. Methods: Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethylation450 Bead Chip Array. Results: Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster 3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed ( P < .001). On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters 1 and 2 ( P < .05). Only 1 of 29 CPPs recurred. Conclusions: Methylation profiling ofAbstract: Background: Choroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowledge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence. Methods: Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethylation450 Bead Chip Array. Results: Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster 3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed ( P < .001). On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters 1 and 2 ( P < .05). Only 1 of 29 CPPs recurred. Conclusions: Methylation profiling of choroid plexus tumors reveals 3 distinct subgroups (ie, pediatric low-risk choroid plexus tumors [cluster 1], adult low-risk choroid plexus tumors [cluster 2], and pediatric high-risk choroid plexus tumors [cluster 3]) and may provide useful prognostic information in addition to histopathology. … (more)
- Is Part Of:
- Neuro-oncology. Volume 18:Issue 6(2016:Jun.)
- Journal:
- Neuro-oncology
- Issue:
- Volume 18:Issue 6(2016:Jun.)
- Issue Display:
- Volume 18, Issue 6 (2016)
- Year:
- 2016
- Volume:
- 18
- Issue:
- 6
- Issue Sort Value:
- 2016-0018-0006-0000
- Page Start:
- 790
- Page End:
- 796
- Publication Date:
- 2016-01-28
- Subjects:
- atypical choroid plexus papilloma -- choroid plexus carcinoma -- copy-number alterations -- epigenetics -- prognosis
Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/nov322 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24983.xml